These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2306414)

  • 1. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole.
    Toon S; Ross CE; Gokal R; Rowland M
    Br J Clin Pharmacol; 1990 Feb; 29(2):221-6. PubMed ID: 2306414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of intraperitoneal fluconazole during continuous cycling peritoneal dialysis.
    Dahl NV; Foote EF; Searson KM; Fein JL; Kapoian T; Steward CA; Sherman RA
    Ann Pharmacother; 1998 Dec; 32(12):1284-9. PubMed ID: 9876807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of meropenem in subjects with renal insufficiency.
    Leroy A; Fillastre JP; Etienne I; Borsa-Lebás F; Humbert G
    Eur J Clin Pharmacol; 1992; 42(5):535-8. PubMed ID: 1607000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of fluconazole in renal failure.
    Berl T; Wilner KD; Gardner M; Hansen RA; Farmer B; Baris BA; Henrich WL
    J Am Soc Nephrol; 1995 Aug; 6(2):242-7. PubMed ID: 7579091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis.
    Singlas E; Taburet AM; Landru I; Albin H; Ryckelinck JP
    Eur J Clin Pharmacol; 1987; 31(5):589-93. PubMed ID: 3830244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cefonicid in uraemic patients.
    Fillastre JP; Fourtillan JB; Leroy A; Ramis N; Lefevre MA; Reumont G; Humbert G
    J Antimicrob Chemother; 1986 Aug; 18(2):203-11. PubMed ID: 3759731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of nomifensine in impaired renal function.
    Ringoir S; Lameire N; Munche M; Heptner W; Taeuber K
    Br J Clin Pharmacol; 1977; 4Suppl 2(Suppl 2):129S-134S. PubMed ID: 334214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis.
    Debruyne D; Ryckelynck JP; Moulin M; Hurault de Ligny B; Levaltier B; Bigot MC
    Clin Pharmacokinet; 1990 Jun; 18(6):491-8. PubMed ID: 2354592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.
    Lorusso V; Taroni P; Alvino S; Spinazzi A
    Invest Radiol; 2001 Jun; 36(6):309-16. PubMed ID: 11410750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of residual renal function with an increase in dialysis: haemodialysis versus peritoneal dialysis.
    Teruel-Briones JL; Fernández-Lucas M; Rivera-Gorrin M; Ruiz-Roso G; Díaz-Domínguez M; Rodríguez-Mendiola N; Quereda-Rodríguez-Navarro C
    Nefrologia; 2013; 33(5):640-9. PubMed ID: 24089155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis.
    Fillastre JP; Taburet AM; Fialaire A; Etienne I; Bidault R; Singlas E
    Drugs Exp Clin Res; 1993; 19(1):25-32. PubMed ID: 8223137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of guanfacine in patients with normal and impaired renal function.
    Kirch W; Köhler H; Braun W
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):33S-35S. PubMed ID: 6994776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of rufloxacin in patients with impaired renal function.
    Perry G; Mant TG; Morrison PJ; Sacks S; Woodcook J; Wise R; Imbimbo BP
    Antimicrob Agents Chemother; 1993 Apr; 37(4):637-41. PubMed ID: 8388194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of residual renal function in patients undergoing maintenance haemodialysis or continuous ambulatory peritoneal dialysis.
    Rottembourg J; Issad B; Gallego JL; Degoulet P; Aime F; Gueffaf B; Legrain M
    Proc Eur Dial Transplant Assoc; 1983; 19():397-403. PubMed ID: 6878254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment.
    Flor S; Guay D; Opsahl J; Tack K; Matzke G
    Int J Clin Pharmacol Res; 1991; 11(3):115-21. PubMed ID: 1809697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose kinetics and dosage of mecillinam in renal failure and haemodialysis.
    Schapira A
    Clin Pharmacokinet; 1984; 9(4):364-70. PubMed ID: 6088153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of azlocillin in chronic renal failure and hemodialysis patients].
    Fillastre JP; Humbert G; Leroy A; Godin M
    Presse Med; 1984 Mar; 13(13):797-801. PubMed ID: 6231597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphate handling by end-stage kidneys and benefits of residual renal function on phosphate removal in patients on haemodialysis.
    Iwasawa H; Nakao T; Matsumoto H; Okada T; Nagaoka Y; Wada T
    Nephrology (Carlton); 2013 Apr; 18(4):285-91. PubMed ID: 23432763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of furosemide in children with chronic renal failure undergoing regular haemodialysis.
    Riva E; Fossali E; Bettinelli A
    Eur J Clin Pharmacol; 1982; 21(4):303-6. PubMed ID: 7056274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis.
    Spigset O; Hägg S; Stegmayr B; Dahlqvist R
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):699-703. PubMed ID: 11214779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.